Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Advanced Drug Development a Reality with UK's Most Powerful Nuclear Magnetic Resonance Facility

By LabMedica International staff writers
Posted on 30 Nov 2010
UK researchers are gaining new insights into vital high tech engineering materials and novel pharmaceuticals due to the creation of the UK's most powerful nuclear magnetic resonance (NMR) device for solids now sited in a national research facility.

The new UK 850 MHz Solid-State NMR Facility at the University of Warwick's (UK) Center for Magnetic Resonance was launched in the University's Millburn House on October 28, 2010. More...
It is a national facility open to a large range of researchers across the United Kingdom and has been made possible by the award of a GBP 3.7 million grant from the Engineering and Physical Sciences Research Council (EPSRC; Swindon, Wiltshire, UK) and the Biotechnology and Biological Sciences Research Council (BBSRC; Swindon, Wiltshire, UK).

The new facility was formally launched by David Delpy, the chief executive of EPSRC at a special event, which was attended by researchers from all the main facility partners (Universities of Warwick, Cambridge, Durham, Nottingham, Glasgow, and St. Andrews). David Delpy said, "The EPSRC are pleased to have supported the UK's internationally leading research for over 15 years. NMR spectroscopy is a vital analytical tool science. It is a powerful technique that can provide detailed information on the topology, dynamics, and three-dimensional structure of molecules in solution and the solid state.”

Prof. Mark Smith, deputy vice-chancellor of the University of Warwick, said, "This facility provides a significant leap in the capability available to the UK's NMR spectroscopy researchers that allows us to compete with the very best in the world. This was possible through the coordinated efforts of a wide range of researchers and funders and is a model of such a partnership for developing such facilities for the UK in the future. It is certain to provide us with new insights into everything from potential new pharmaceuticals to innovate materials for the next generation of catalytic convertors.”

Related Links:
University of Warwick
UK Engineering and Physical Sciences Research Council
UK Biotechnology and Biological Sciences Research Council


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.